Erschienen in:
Current Opinion in Organ Transplantation, 27 (2022) 5, Seite 466-473
Sprache:
Englisch
DOI:
10.1097/mot.0000000000001008
ISSN:
1087-2418;
1531-7013
Entstehung:
Anmerkungen:
Beschreibung:
Purpose of review Ex-situ machine perfusion for both heart (HTx) and lung transplantation (LuTx) reduces ischemia–reperfusion injury (IRI), allows for greater flexibility in geographical donor management, continuous monitoring, organ assessment for extended evaluation, and potential reconditioning of marginal organs. In this review, we will delineate the impact of machine perfusion, characterize novel opportunities, and outline potential challenges lying ahead to improve further implementation. Recent findings Due to the success of several randomized controlled trials (RCT), comparing cold storage to machine perfusion in HTx and LuTx, implementation and innovation continues. Indeed, it represents a promising interface for organ-specific therapies targeting IRI, allo-immune responses, and graft reconditioning. These mostly experimental efforts range from genetic approaches and nanotechnology to cellular therapies, involving mesenchymal stem cell application. Despite tremendous potential, prior to clinical transition, more data is needed. Summary Collectively, machine perfusion constitutes the vanguard in thoracic organ transplantation research with extensive potential for expanding the donor pool, enhancing transplant outcomes as well as developing novel therapy approaches.